1. Home
  2. MSD vs ASMB Comparison

MSD vs ASMB Comparison

Compare MSD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Debt Fund Inc.

MSD

Morgan Stanley Emerging Markets Debt Fund Inc.

HOLD

Current Price

$7.35

Market Cap

146.8M

Sector

Finance

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$36.12

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSD
ASMB
Founded
1993
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.8M
553.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
MSD
ASMB
Price
$7.35
$36.12
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$43.40
AVG Volume (30 Days)
70.2K
124.4K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
11.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$37,191,000.00
Revenue This Year
N/A
$42.01
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.30
52 Week Low
$6.11
$7.75
52 Week High
$7.46
$39.71

Technical Indicators

Market Signals
Indicator
MSD
ASMB
Relative Strength Index (RSI) 51.13 57.82
Support Level $7.35 $35.05
Resistance Level $7.41 $38.82
Average True Range (ATR) 0.05 1.91
MACD 0.00 -0.32
Stochastic Oscillator 60.71 42.70

Price Performance

Historical Comparison
MSD
ASMB

About MSD Morgan Stanley Emerging Markets Debt Fund Inc.

Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: